Einar M. Sigurdsson

15.4k citations

120 papers · 7.0k indexed · 3 hit papers · h-index 43

Physiology top 0.2%
Molecular Biology top 2%
Neurology top 0.2%
Pharmacology top 0.5%
Cellular and Molecular Neuroscience top 1%

Co-authors: Erin E. Congdon Thomas Wısnıewskı Blas Frangione David Quartermain Allal Boutajangout Claudio Soto Ayodeji A. Asuni Henrieta Scholtzova
Topics: Alzheimer's disease research and treatments (100 papers)Neuroinflammation and Neurodegeneration Mechanisms (44 papers)Neuroscience and Neuropharmacology Research (34 papers)
Cited by: Neurology Physiology Biological Psychiatry
Journals: Journal of Biological Chemistry Nature Medicine Journal of Neuroscience
Partner nations: United States France Denmark

In The Last Decade

Einar M. Sigurdsson

116 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tau-targeting therapies for Alzheimer disease

2018 809 citations Erin E. Congdon, Einar M. Sigurdsson profile →
β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy

1998 742 citations Claudio Soto, Einar M. Sigurdsson et al. Nature Medicine profile →
Tau-targeting therapies for Alzheimer disease: current status and future directions

2023 168 citations Erin E. Congdon, Yixiang Jiang et al. profile →

Peers

Countries citing papers authored by Einar M. Sigurdsson

Since Specialization

Citations

This map shows the geographic impact of Einar M. Sigurdsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Einar M. Sigurdsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Einar M. Sigurdsson more than expected).

Fields of papers citing papers by Einar M. Sigurdsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Einar M. Sigurdsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Einar M. Sigurdsson. The network helps show where Einar M. Sigurdsson may publish in the future.

Co-authorship network of co-authors of Einar M. Sigurdsson

This figure shows the co-authorship network connecting the top 25 collaborators of Einar M. Sigurdsson. A scholar is included among the top collaborators of Einar M. Sigurdsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Einar M. Sigurdsson. Einar M. Sigurdsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau 2023 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Dag Sehlin,Greta Hultqvist,Einar M. Sigurdsson,Stina Syvänen,Yu‐Shin Ding	2
2	Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology 2023 ·Science Advances ·Yixiang Jiang,(unknown),(unknown),(unknown),Qian Wu,(unknown),Mengyu Liu,Min‐Hao Kuo,Xiang‐Peng Kong,Erin E. Congdon,Einar M. Sigurdsson	14
3	Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity 2022 ·EBioMedicine ·Erin E. Congdon,(unknown),Yixiang Jiang,(unknown),(unknown),Yan Lin,Mengyu Liu,Min‐Hao Kuo,Xiang‐Peng Kong,Einar M. Sigurdsson	18
4	Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model 2020 ·Frontiers in Neurology ·(unknown),Yan Deng,Qian Wu,(unknown),Erin E. Congdon,Einar M. Sigurdsson	13
5	Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein 2018 ·Scientific Reports ·(unknown),Jan T. Pedersen,Lars Østergaard Pedersen,Christiane Volbracht,Einar M. Sigurdsson,Xiang‐Peng Kong	23
6	In Vivo Imaging of Tauopathy in Mice 2018 ·Methods in molecular biology ·(unknown),Qian Wu,Yan Lin,(unknown),Hameetha B. Rajamohamedsait,Einar M. Sigurdsson	6
7	In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI 2018 ·Methods in molecular biology ·Anne Bertrand,Marı́a Adela Barón,Dung Minh Hoang,(unknown),(unknown),Einar M. Sigurdsson,Youssef Zaim Wadghiri	3
8	Antibody-DerivedIn VivoImaging of Tau Pathology 2014 ·Journal of Neuroscience ·(unknown),Yan Lin,(unknown),Hameetha B. Rajamohamedsait,Pavan Krishnamurthy,Einar M. Sigurdsson	48
9	Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance 2013 ·Journal of Biological Chemistry ·Erin E. Congdon,Jiaping Gu,Hameetha Banu Rajamohamed Sait,Einar M. Sigurdsson	159
10	Murine models of Alzheimer's disease and their use in developing immunotherapies 2010 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Thomas Wısnıewskı,Einar M. Sigurdsson	61
11	Alzheimer’s disease: challenges ahead 2010 ·Frontiers in Psychiatry ·Einar M. Sigurdsson	1
12	Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging 2008 ·Journal of Neuroscience Research ·Henrieta Scholtzova,Youssef Zaim Wadghiri,(unknown),Einar M. Sigurdsson,Yongsheng Li,David Quartermain,Pradeep Banerjee,Thomas Wısnıewskı	104
13	Amyloid proteins : methods and protocols 2005 ·Humana Press eBooks ·Einar M. Sigurdsson,Miguel Calero,Marı́a Gasset	74
14	Histological Staining of Amyloid-β in Mouse Brains 2005 ·Humana Press eBooks ·Einar M. Sigurdsson	11
15	Conformation as Therapeutic Target in the Prionoses and Other Neurodegenerative Conditions 2003 ·Humana Press eBooks ·Thomas Wısnıewskı,Einar M. Sigurdsson,Pièrre Aucouturier,Blas Frangione	5
16	Immunization Delays the Onset of Prion Disease in Mice 2002 ·American Journal Of Pathology ·Einar M. Sigurdsson,David R. Brown,Maki Daniels,Richard J. Kascsak,Regina Kascsak,Richard Carp,Harry C. Meeker,Blas Frangione,Thomas Wısnıewskı	150
17	Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging 2002 ·Neurobiology of Disease ·Joseph F. Poduslo,Thomas M. Wengenack,Geoffry L. Curran,Thomas Wısnıewskı,Einar M. Sigurdsson,(unknown),Bret Borowski,Clifford R. Jack	165
18	Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice 2001 ·American Journal Of Pathology ·Einar M. Sigurdsson,Henrieta Scholtzova,Pankaj Mehta,Blas Frangione,Thomas Wısnıewskı	210
19	β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapybreakdown → 1998 ·Nature Medicine ·Claudio Soto,Einar M. Sigurdsson,Laura Morelli,Rashmi Kumar,Eduardo M. Castaño,Blas Frangione	742
20	Local and distant histopathological effects of unilateral amyloid-β 25–35 injections into the amygdala of young F344 rats 1996 ·Neurobiology of Aging ·Einar M. Sigurdsson,Stanley A. Lorens,Matthew J. Hejna,(unknown),John M. Lee	43

About Einar M. Sigurdsson

Einar M. Sigurdsson is a scholar working on Neurology, Physiology and Cellular and Molecular Neuroscience, having authored 120 papers that have together received 7.0k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (100 papers), Neuroinflammation and Neurodegeneration Mechanisms (44 papers) and Neuroscience and Neuropharmacology Research (34 papers). The work is most often cited by research in Neurology (2.1k citations), Physiology (5.1k citations) and Biological Psychiatry (378 citations). Einar M. Sigurdsson has collaborated with scholars based in United States, France and Denmark. Frequent co-authors include Erin E. Congdon, Thomas Wısnıewskı, Blas Frangione, David Quartermain, Allal Boutajangout, Claudio Soto, Ayodeji A. Asuni, Henrieta Scholtzova, Laura Morelli and Eduardo M. Castaño. Their work appears in journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Neuroscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact